KATHERINE OLMSTEAD: Open Payments
NPI 1699211029 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,166 in 46 payments from 16 companies in 2025. Trend: 2023 $432 · 2024 $462 · 2025 $1,166
Food & beverage: $1,166
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $397 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $149 |
| Novo Nordisk Inc | 6 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $100 |
| PFIZER INC. | 3 | $67 |
| GlaxoSmithKline, LLC. | 2 | $44 |
| Astellas Pharma US Inc | 2 | $44 |
| Exeltis, USA Inc. | 2 | $41 |
| Pharmacosmos Therapeutics Inc. | 1 | $34 |
| Exact Sciences Corporation | 1 | $31 |
Products named: VRAYLAR, NEFFY, QULIPTA, TRINTELLIX, Ozempic, AREXVY, Veozah, Wegovy.
Industry payments across PA — which companies pay providers there.
